|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GAP43 |
Gene summary for GAP43 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GAP43 | Gene ID | 2596 |
| Gene name | growth associated protein 43 | |
| Gene Alias | B-50 | |
| Cytomap | 3q13.31 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | P17677 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2596 | GAP43 | P10T-E | Human | Esophagus | ESCC | 2.05e-07 | 1.37e-01 | 0.116 |
| 2596 | GAP43 | P19T-E | Human | Esophagus | ESCC | 4.34e-05 | 6.93e-01 | 0.1662 |
| 2596 | GAP43 | P24T-E | Human | Esophagus | ESCC | 3.97e-04 | 2.28e-01 | 0.1287 |
| 2596 | GAP43 | P26T-E | Human | Esophagus | ESCC | 7.90e-03 | 9.73e-02 | 0.1276 |
| 2596 | GAP43 | P32T-E | Human | Esophagus | ESCC | 1.62e-13 | 5.02e-01 | 0.1666 |
| 2596 | GAP43 | P74T-E | Human | Esophagus | ESCC | 1.08e-02 | 1.24e-01 | 0.1479 |
| 2596 | GAP43 | P76T-E | Human | Esophagus | ESCC | 3.97e-04 | 1.04e-01 | 0.1207 |
| 2596 | GAP43 | P107T-E | Human | Esophagus | ESCC | 7.61e-06 | 2.18e-01 | 0.171 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190211514 | Esophagus | ESCC | regulation of organelle assembly | 116/8552 | 186/18723 | 3.15e-06 | 3.53e-05 | 116 |
| GO:003109910 | Esophagus | ESCC | regeneration | 122/8552 | 198/18723 | 4.26e-06 | 4.57e-05 | 122 |
| GO:00420636 | Esophagus | ESCC | gliogenesis | 172/8552 | 301/18723 | 3.75e-05 | 3.04e-04 | 172 |
| GO:00311033 | Esophagus | ESCC | axon regeneration | 37/8552 | 52/18723 | 1.75e-04 | 1.14e-03 | 37 |
| GO:006156415 | Esophagus | ESCC | axon development | 251/8552 | 467/18723 | 2.41e-04 | 1.49e-03 | 251 |
| GO:006049118 | Esophagus | ESCC | regulation of cell projection assembly | 110/8552 | 188/18723 | 2.60e-04 | 1.58e-03 | 110 |
| GO:00100016 | Esophagus | ESCC | glial cell differentiation | 129/8552 | 225/18723 | 2.73e-04 | 1.65e-03 | 129 |
| GO:003432918 | Esophagus | ESCC | cell junction assembly | 227/8552 | 420/18723 | 3.06e-04 | 1.83e-03 | 227 |
| GO:00311024 | Esophagus | ESCC | neuron projection regeneration | 41/8552 | 60/18723 | 3.25e-04 | 1.91e-03 | 41 |
| GO:012003218 | Esophagus | ESCC | regulation of plasma membrane bounded cell projection assembly | 108/8552 | 186/18723 | 4.37e-04 | 2.46e-03 | 108 |
| GO:00486785 | Esophagus | ESCC | response to axon injury | 51/8552 | 83/18723 | 2.74e-03 | 1.16e-02 | 51 |
| GO:000740915 | Esophagus | ESCC | axonogenesis | 219/8552 | 418/18723 | 3.14e-03 | 1.31e-02 | 219 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GAP43 | SNV | Missense_Mutation | novel | c.536N>T | p.Ala179Val | p.A179V | P17677 | protein_coding | deleterious(0.01) | probably_damaging(0.927) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GAP43 | SNV | Missense_Mutation | c.449G>T | p.Gly150Val | p.G150V | P17677 | protein_coding | deleterious(0.01) | benign(0.343) | TCGA-BH-A0H6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GAP43 | SNV | Missense_Mutation | novel | c.401N>A | p.Pro134His | p.P134H | P17677 | protein_coding | deleterious(0.02) | possibly_damaging(0.65) | TCGA-BH-A5IZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| GAP43 | SNV | Missense_Mutation | rs764694995 | c.772N>T | p.Arg258Trp | p.R258W | P17677 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-D8-A1X6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
| GAP43 | SNV | Missense_Mutation | c.129G>T | p.Trp43Cys | p.W43C | P17677 | protein_coding | tolerated(0.18) | benign(0) | TCGA-E2-A14X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| GAP43 | SNV | Missense_Mutation | novel | c.511N>A | p.Ala171Thr | p.A171T | P17677 | protein_coding | tolerated(0.13) | benign(0.112) | TCGA-OL-A5RV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
| GAP43 | deletion | Frame_Shift_Del | novel | c.371_381delNNNNNNNNNNN | p.Glu125SerfsTer7 | p.E125Sfs*7 | P17677 | protein_coding | TCGA-AN-A0FF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| GAP43 | SNV | Missense_Mutation | c.165N>C | p.Lys55Asn | p.K55N | P17677 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C5-A7UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| GAP43 | SNV | Missense_Mutation | novel | c.271N>G | p.Lys91Glu | p.K91E | P17677 | protein_coding | tolerated(0.06) | possibly_damaging(0.609) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| GAP43 | SNV | Missense_Mutation | c.598N>A | p.Glu200Lys | p.E200K | P17677 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-FU-A5XV-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |